Live Webinar for our Opening Plenary Session:
Trends in New Oncology Treatments
Record number of new oncology treatments have been approved in recent years, bringing new treatment options to patients. Although recent progress has deepened our understanding of the disease and has also brought on unprecedented new possibilities for personalized medicine, there are still many cancer types for which there are no, or minimally, effective therapy. Leaders in the field will discuss the latest breakthroughs in oncology research, the impact of COVID-19 on oncology drug development and insights on future trends in oncology treatment and the financial landscape for these promising new therapies.
The panel will focus on:
- Latest development in oncology R&D
- Including Real World Evidence and its uses to glean information about patients with molecular subsets of cancers
- Advancements in Cell Therapy
- What was hot at ESMO
- Perspectives on investment landscape in oncology
PhD, Venture Partner, RA Capital, Management
Speaker and Moderator Bios
Director, Product Management, Clinico-Genomics, Flatiron Health
Dana is a senior product manager on the clinico-genomics team at Flatiron. Prior to Flatiron, she worked in healthcare strategy consulting, supporting stakeholders across the system (including public and private payers, technology companies, and regulators) in developing strategies for healthcare reform reform.
Dr. Elisa Kieback
Chief Executive Officer, T-knife
Elisa is Chief Executive Officer and co-founded T-knife together with Prof. Thomas Blankenstein. She studied Biology at the Universities of Dresden, Heidelberg, and Glasgow and obtained a PhD in Immunology. She was named one of the 100 most visionary women in 2006 (by the initiative „Germany – Land of Ideas”). In 2010, she received the Marthe-Vogt Award honoring outstanding young female scientists. For the past 15 years she has studied TCRs and their therapeutic application as a researcher. Her work resulted in numerous patents in the field of adoptive T cell therapy.
CEO, President, and Director, Boundless Bio
Zachary (“Zach”) Hornby has served in executive and director roles for multiple private and public biotechnology companies. Prior to joining Boundless Bio, Zach was Chief Executive Officer, President and a Director at Optera Therapeutics Corp, a company that was developing multiple clinical-stage cellular therapies that had been innovated at MD Anderson Cancer Center. Before that, he was Chief Operating Officer at Ignyta, where he oversaw development of the company’s portfolio of four clinical stage therapeutics and was the team leader for the company’s lead program, entrectinib, which was the first drug in pharmaceutical history to garner the coveted BTD (FDA), PRIME (EMA) and Sakigake (PMDA) designations. In that role, he also led the business development process that resulted in Ignyta’s acquisition by Roche for $2 billion; after the Roche acquisition, Zach served as the Ignyta site head where he was responsible for overseeing the integration into Roche. Zach holds B.S. and M.S. degrees in biology, with a concentration in neuroscience, from Stanford University and an MBA from Harvard Business School.
PhD, Venture Partner, RA Capital Management
Stephanie is a Venture Partner at RA Capital Management. Stephanie’s primary responsibility at RA Capital is to identify compelling assets to help facilitate new company creation or investments in emerging seed-stage companies. Prior to RA, Stephanie was at Evotec, where she served as the EVP, Head Academic Partnership and Investments North America & Asia. Prior to Evotec, Stephanie was an International Business Leader Avastin BC/GYN at Hoffmann-La Roche. Before arriving at La Roche, Stephanie spent 12+yrs at Novartis, in varying leadership roles. Her most recent role at Novartis was as the Disease Area Leader in Multiple Myeloma for the Oncology Region Europe. She has a Bachelor's in Egyptology, Latin and Classical Archeology, a Masters in Biochemistry, and a PhD in Biochemistry from Freie Universität Berlin, Germany, and a MPA from Harvard University from the JFK School of Government.